EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Potential of NRF2 Inhibitors—Retinoic Acid, K67, and ML-385—In Overcoming Doxorubicin Resistance in Promyelocytic Leukemia Cells

Michał Juszczak, Paulina Tokarz iD, Katarzyna Woźniak iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms251910257 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Michał Juszczak und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Doxorubicin, Drug Resistance, Neoplasm, Tretinoin. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Doctoral Research Grant of the University of Lodz.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug resistance is one of the major obstacles to the clinical use of doxorubicin, an extensively used chemotherapeutic drug to treat various cancers, including leukemia. Inhibition of the nuclear factor erythroid 2-related factor 2 (NRF2) seems a promising strategy to reverse chemoresistance in cancer cells. NRF2 is a transcription factor that regulates both antioxidant defense and drug detoxification mechanisms. In this study, we investigated the potential of three inhibitors of NRF2—K67, retinoic acid and ML-385—to overcome doxorubicin resistance in promyelocytic leukemia HL-60 cells. For this purpose, low-dose doxorubicin was used to establish doxorubicin-resistant HL-60/DR cells. The expression of NRF2 and its main repressor, Kelch-like ECH-associated protein 1 (KEAP1), at mRNA and protein levels was examined. HL-60/DR cells overexpressed NRF2 at mRNA and protein levels and down-regulated KEAP1 protein compared to drug-sensitive HL-60 cells. The effects of NRF2 inhibitors on doxorubicin-resistant HL-60/DR cell viability, apoptosis, and intracellular reactive oxygen species (ROS) levels were analyzed. We observed that NRF2 inhibitors significantly sensitized doxorubicin-resistant HL-60/DR cells to doxorubicin, which was associated with increased intracellular ROS levels and the expression of CAS-9, suggesting the participation of the mitochondrial-dependent apoptosis pathway. Furthermore, ML-385 inhibitor was used to study the expression of NRF2–KEAP1 pathway genes. NRF2 gene and protein expression remained unchanged; however, we noted the down-regulation of KEAP1 protein upon ML-385 treatment. Additionally, the expression of NRF2-regulated antioxidant and detoxification genes including SOD2, HMOX2, and GSS was maintained upon ML-385 treatment. In conclusion, our results demonstrated that all the studied inhibitors, namely K67, retinoic acid, and ML-385, increased the efficacy of doxorubicin in doxorubicin-resistant HL-60/DR cells, and suggested a potential strategy of combination therapy using NRF2 inhibitors and doxorubicin in overcoming doxorubicin resistance in leukemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NF-E2-Related Factor 2DoxorubicinDrug Resistance, NeoplasmTretinoinLeukemia, Promyelocytic, AcuteHumansHL-60 CellsReactive Oxygen SpeciesKelch-Like ECH-Associated Protein 1ApoptosisCell Survival

Stichwörter der Autor:innen

NRF2apoptosisdoxorubicinleukemiareactive oxygen speciesresistance

Substanzen

NF-E2-Related Factor 2DoxorubicinTretinoinNFE2L2 protein, humanReactive Oxygen SpeciesKelch-Like ECH-Associated Protein 1KEAP1 protein, human

Autor:innen und Institutionen

  • Department of Molecular Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland.

ORCID-Profile: Paulina Tokarz, Katarzyna Woźniak

Förderung

  • Doctoral Research Grant of the University of Lodz

Zitieren

APA

Juszczak, M., Tokarz, P., & Woźniak, K. (2024). Potential of NRF2 Inhibitors—Retinoic Acid, K67, and ML-385—In Overcoming Doxorubicin Resistance in Promyelocytic Leukemia Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms251910257

Vancouver

Juszczak M, Tokarz P, Woźniak K. Potential of NRF2 Inhibitors—Retinoic Acid, K67, and ML-385—In Overcoming Doxorubicin Resistance in Promyelocytic Leukemia Cells. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms251910257

BibTeX
@article{Juszczak2024,
  author = {Juszczak, Michał and Tokarz, Paulina and Woźniak, Katarzyna},
  title = {Potential of NRF2 Inhibitors—Retinoic Acid, K67, and ML-385—In Overcoming Doxorubicin Resistance in Promyelocytic Leukemia Cells},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms251910257}
}
Kostenlos starten →